Thyrocare Divests Radiology Subsidiary Nueclear Healthcare for Rs 141.40 Crore
Thyrocare Technologies Ltd 路 Others (Uncategorized) 路 21 Sept 2026, 8:36 pm
Thyrocare Divests Radiology Subsidiary Nueclear Healthcare for Rs 141.40 Crore Thyrocare Technologies approved divesting 100% of its wholly owned subsidiary Nueclear Healthcare Limited (NHL) to Trovera Healthcare for ~Rs 141.40 cr to focus on core pathology. The consideration comprises Rs 81.90 cr in cash (subject to working capital adjustments) and Rs 59.50 cr via 42,500 CCPS of Trovera (~4.5% fully diluted stake). Simultaneously, Thyrocare will acquire NHL's Gurugram and Hyderabad lab properties for Rs 20.59 cr. NHL contributed Rs 44.62 cr (5.38%) to FY26 consolidated revenue. The transaction expects completion by 30th Nov'26, subject to shareholder approval.
Original exchange filing (PDF)
More announcements from Thyrocare Technologies Ltd
- Please find the enclosed announcement. 路 06 Nov 2026
- Please find the enclosed intimation. 路 06 Nov 2026
- Please find attached the Earnings Call Transcript held on October 29, 2026 路 02 Nov 2026
- Please find attached Intimation regarding the Execution of Share Purchase Agreement 路 30 Oct 2026
- Audio Recording of Earnings Conference Call for the Quarter and Half Year Ended September 30, 2026 路 30 Oct 2026
- Please find attached the Investor Presentation on the unaudited financial results (standalone and consolidated) for the quarter and half year ended on September 30, 2026 路 29 Oct 2026
- Please find attached the Press Release on the unaudited financial results (Standalone and Consolidated) for the quarter and half year ended on September 30, 2026 路 29 Oct 2026
- Please find enclosed the unaudited standalone and consolidated financial results of the Company for the quarter and half year ended on September 30, 2026 路 29 Oct 2026
